PHARMACOECONOMIC EVALUATION OF COSTS AND BENEFITS OF TREATING ELDERLY PATIENTS WITH CORONARY HEART DISEASE
Non failing growth of the number of cardiovascular diseases in Russia leads to the fact that people become handicaps early, may lead to death, lower quality of life of population. The cost of treatment is taken on by medical insurances and the patient him/ or herself, and annually the cost only growths. It is necessary, while there is an economic crisis, and limited budget have more rationale in use of the available funds. There has been done a research, in the work process, of two groups of patients, who had ischemic heart disease, who were receiving cardiket and monochinkve inpatient therapy. There has been done an appraisal of social-demographic structure of patients with coronary heart disease, there has been conducted analysis of clinical-economical parameters of the assortment that has been used, Was given pharmacoeco-nomical appraisal of the conducted treatment and appraisal of the quality of life. QUAL of the patient's with the disease before and after the treatment. It has been proven an improvement of quality of life in the patients with coronary heart disease.